Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Apoptosis therapy: driving cancers down the road to ruin

Nature Medicine volume 19, pages 131–133 (2013)Cite this article

Subjects

BH3 mimetics are a class of anticancer agents that hold the promise to trigger the central apoptotic machinery to set cancer cells on the road to ruin. Now, a new agent that selectively targets BCL-2, ABT-199, has been developed, with exciting preclinical and clinical results (pages 202–208).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The friends and foes of BCL-2.

Marina Corral

References

  1. Souers, A.J. et al. Nat. Med. 19, 202–208 (2013).

    Article  CAS  Google Scholar 

  2. Green, D.R. Means to an End: Apoptosis and Other Cell Death Mechanisms (CSHL Press, 2011).

    Google Scholar 

  3. Chipuk, J.E., Moldoveanu, T., Llambi, F., Parsons, M.J. & Green, D.R. Mol. Cell 37, 299–310 (2010).

    Article  CAS  Google Scholar 

  4. Vo, T.T. et al. Cell 151, 344–355 (2012).

    Article  CAS  Google Scholar 

  5. Oltersdorf, T. et al. Nature 435, 677–681 (2005).

    Article  CAS  Google Scholar 

  6. Tse, C. et al. Cancer Res. 68, 3421–3428 (2008).

    Article  CAS  Google Scholar 

  7. van Delft, M.F. et al. Cancer Cell 10, 389–399 (2006).

    Article  CAS  Google Scholar 

  8. Mason, K.D. et al. Cell 128, 1173–1186 (2007).

    Article  CAS  Google Scholar 

  9. Beroukhim, R. et al. Nature 463, 899–905 (2010).

    Article  CAS  Google Scholar 

  10. Gavathiotis, E., Reyna, D.E., Bellairs, J.A., Leshchiner, E.S. & Walensky, L.D. Nat. Chem. Biol. 8, 639–645 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Douglas R. Green is in the Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.,

    Douglas R. Green

  2. Henning Walczak is at the Centre for Cell Death, Cancer and Inflammation, University College London Cancer Institute, London, UK.,

    Henning Walczak

Authors
  1. Douglas R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henning Walczak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Douglas R. Green or Henning Walczak.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, D., Walczak, H. Apoptosis therapy: driving cancers down the road to ruin. Nat Med 19, 131–133 (2013). https://doi.org/10.1038/nm.3076

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3076

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing